Trial Profile
Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer - Phase II study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- 24 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2011 New trial record